SHOW DIRECTORY
Yet Another Value Podcast
Andrew Walker interviews investors about actionable value and event-driven ideas, with each episode centered on a company, security, or investment thesis.
SOURCE DESCRIPTION · RSS
$HIMS: Paul Cerro wouldn't trust the CEO to walk his dog. He's still long. Why? | Cedar Grove
Cerro’s HIMS thesis shifts attention from peptide launches to the data and labs layer: subscriber counts have “barely grown” for three quarters, making retention the lever for LTV and payback.The August 10 print will test Eucalyptus-driven revenue upside against lower EBITDA guidance, the first full Novo Nordisk partnership quarter, and execution by management Cerro says he does not trust.
Lake Cornelia Capital's Judd Arnold on $TOI and a bunch of other stuff
Judd Arnold’s process now favors liquid inflections where small “junior varsity positions” can become large once “people will care,” rather than merely cheap, illiquid stocks.His $TOI thesis is that capitated oncology can redirect prescribing toward lower-cost regimens, with Florida contracts at roughly $35 PMPM versus $3 in California, but clinician control, reimbursement capture, and the post-SPAC SG&A blowout remain execution risks.
David Capital Partners' Adam Patinkin on how Lifecore $LFCR has differentiated it's CDMO business
Lifecore is being repositioned as a pure-play CDMO for sterile fill-finish of complex injectables, where regulatory switching costs and scarce capacity support customer stickiness.The new CEO targets EBITDA margins of at least 25% from roughly 15%, while customer ramp, $150 million of debt, and an 80% probability of change-of-control by 2028 make execution and timing central.